Advantages of Neoral conversion in renal transplant patients

G. Vennarecci, F. Pisani, G. Tisone, O. Buonomo, A. Famulari, C. U. Casciani

Research output: Contribution to journalArticle

Abstract

Background. Sandimmun Neoral is a microemulsion formulation of Sandimmun cyclosporin (Cya) with predictable pharmacokinetics, superior absorption and less dependent upon bile production. Recently Neoral replaced the old Cya in the clinical ground. Methods. The aim of this study was to assess the effectiveness, safety and advantages of this conversion in 90 adult renal transplant patients with stable renal function transplanted at least 24 months earlier. There were 48 males and 42 females with a mean age of 39 years (range: 18-56). Mean interval from transplant to conversion was 3.6 years (range: 2.7-5.4). Conversion rate was 1:1. Mean Neoral dose at conversion was 3.8 mg/kg/day (range: 2.1-5.7). Results. One month after conversion mean Neoral dose was 3.4 mg/kg/day (range: 2.2-3.9) and at six months was 3.2 mg/kg/day (range: 2.1-4). Serum creatinine and CyA trough levels remained stable. We did not observed rejection episodes or infections. The incidence of side effects due to CyA was slightly increased and there were not differences in terms of arterial pressure values and number of antihypertensive drugs given. Conclusions. The conclusion is drown that conversion to Neoral is safe and results in rapid attainment of therapeutic trough levels. Six months after conversion the mean Neoral dose was decreased of 0.6 mg/kg/die per patient.

Original languageEnglish
Pages (from-to)161-164
Number of pages4
JournalMinerva Urologica e Nefrologica
Volume50
Issue number2
Publication statusPublished - 1998

Fingerprint

Cyclosporine
Transplants
Kidney
Bile
Antihypertensive Agents
Creatinine
Arterial Pressure
Pharmacokinetics
Safety
Incidence
Infection
Serum

Keywords

  • Cyclosporine therapeutic use
  • Immuno-suppressive agents, therapeutic use
  • Kidney transplantation

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Vennarecci, G., Pisani, F., Tisone, G., Buonomo, O., Famulari, A., & Casciani, C. U. (1998). Advantages of Neoral conversion in renal transplant patients. Minerva Urologica e Nefrologica, 50(2), 161-164.

Advantages of Neoral conversion in renal transplant patients. / Vennarecci, G.; Pisani, F.; Tisone, G.; Buonomo, O.; Famulari, A.; Casciani, C. U.

In: Minerva Urologica e Nefrologica, Vol. 50, No. 2, 1998, p. 161-164.

Research output: Contribution to journalArticle

Vennarecci, G, Pisani, F, Tisone, G, Buonomo, O, Famulari, A & Casciani, CU 1998, 'Advantages of Neoral conversion in renal transplant patients', Minerva Urologica e Nefrologica, vol. 50, no. 2, pp. 161-164.
Vennarecci G, Pisani F, Tisone G, Buonomo O, Famulari A, Casciani CU. Advantages of Neoral conversion in renal transplant patients. Minerva Urologica e Nefrologica. 1998;50(2):161-164.
Vennarecci, G. ; Pisani, F. ; Tisone, G. ; Buonomo, O. ; Famulari, A. ; Casciani, C. U. / Advantages of Neoral conversion in renal transplant patients. In: Minerva Urologica e Nefrologica. 1998 ; Vol. 50, No. 2. pp. 161-164.
@article{7287f65a052a45dba89c08a4d608cf15,
title = "Advantages of Neoral conversion in renal transplant patients",
abstract = "Background. Sandimmun Neoral is a microemulsion formulation of Sandimmun cyclosporin (Cya) with predictable pharmacokinetics, superior absorption and less dependent upon bile production. Recently Neoral replaced the old Cya in the clinical ground. Methods. The aim of this study was to assess the effectiveness, safety and advantages of this conversion in 90 adult renal transplant patients with stable renal function transplanted at least 24 months earlier. There were 48 males and 42 females with a mean age of 39 years (range: 18-56). Mean interval from transplant to conversion was 3.6 years (range: 2.7-5.4). Conversion rate was 1:1. Mean Neoral dose at conversion was 3.8 mg/kg/day (range: 2.1-5.7). Results. One month after conversion mean Neoral dose was 3.4 mg/kg/day (range: 2.2-3.9) and at six months was 3.2 mg/kg/day (range: 2.1-4). Serum creatinine and CyA trough levels remained stable. We did not observed rejection episodes or infections. The incidence of side effects due to CyA was slightly increased and there were not differences in terms of arterial pressure values and number of antihypertensive drugs given. Conclusions. The conclusion is drown that conversion to Neoral is safe and results in rapid attainment of therapeutic trough levels. Six months after conversion the mean Neoral dose was decreased of 0.6 mg/kg/die per patient.",
keywords = "Cyclosporine therapeutic use, Immuno-suppressive agents, therapeutic use, Kidney transplantation",
author = "G. Vennarecci and F. Pisani and G. Tisone and O. Buonomo and A. Famulari and Casciani, {C. U.}",
year = "1998",
language = "English",
volume = "50",
pages = "161--164",
journal = "Minerva Urologica e Nefrologica",
issn = "0393-2249",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Advantages of Neoral conversion in renal transplant patients

AU - Vennarecci, G.

AU - Pisani, F.

AU - Tisone, G.

AU - Buonomo, O.

AU - Famulari, A.

AU - Casciani, C. U.

PY - 1998

Y1 - 1998

N2 - Background. Sandimmun Neoral is a microemulsion formulation of Sandimmun cyclosporin (Cya) with predictable pharmacokinetics, superior absorption and less dependent upon bile production. Recently Neoral replaced the old Cya in the clinical ground. Methods. The aim of this study was to assess the effectiveness, safety and advantages of this conversion in 90 adult renal transplant patients with stable renal function transplanted at least 24 months earlier. There were 48 males and 42 females with a mean age of 39 years (range: 18-56). Mean interval from transplant to conversion was 3.6 years (range: 2.7-5.4). Conversion rate was 1:1. Mean Neoral dose at conversion was 3.8 mg/kg/day (range: 2.1-5.7). Results. One month after conversion mean Neoral dose was 3.4 mg/kg/day (range: 2.2-3.9) and at six months was 3.2 mg/kg/day (range: 2.1-4). Serum creatinine and CyA trough levels remained stable. We did not observed rejection episodes or infections. The incidence of side effects due to CyA was slightly increased and there were not differences in terms of arterial pressure values and number of antihypertensive drugs given. Conclusions. The conclusion is drown that conversion to Neoral is safe and results in rapid attainment of therapeutic trough levels. Six months after conversion the mean Neoral dose was decreased of 0.6 mg/kg/die per patient.

AB - Background. Sandimmun Neoral is a microemulsion formulation of Sandimmun cyclosporin (Cya) with predictable pharmacokinetics, superior absorption and less dependent upon bile production. Recently Neoral replaced the old Cya in the clinical ground. Methods. The aim of this study was to assess the effectiveness, safety and advantages of this conversion in 90 adult renal transplant patients with stable renal function transplanted at least 24 months earlier. There were 48 males and 42 females with a mean age of 39 years (range: 18-56). Mean interval from transplant to conversion was 3.6 years (range: 2.7-5.4). Conversion rate was 1:1. Mean Neoral dose at conversion was 3.8 mg/kg/day (range: 2.1-5.7). Results. One month after conversion mean Neoral dose was 3.4 mg/kg/day (range: 2.2-3.9) and at six months was 3.2 mg/kg/day (range: 2.1-4). Serum creatinine and CyA trough levels remained stable. We did not observed rejection episodes or infections. The incidence of side effects due to CyA was slightly increased and there were not differences in terms of arterial pressure values and number of antihypertensive drugs given. Conclusions. The conclusion is drown that conversion to Neoral is safe and results in rapid attainment of therapeutic trough levels. Six months after conversion the mean Neoral dose was decreased of 0.6 mg/kg/die per patient.

KW - Cyclosporine therapeutic use

KW - Immuno-suppressive agents, therapeutic use

KW - Kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031876215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031876215&partnerID=8YFLogxK

M3 - Article

C2 - 9707972

AN - SCOPUS:0031876215

VL - 50

SP - 161

EP - 164

JO - Minerva Urologica e Nefrologica

JF - Minerva Urologica e Nefrologica

SN - 0393-2249

IS - 2

ER -